eningioMas are typically benign tumors that arise from the dura mater. 18 They account for approximately 20%-30% of all intracranial neoplasms and are found mostly in adults. 18, 24, 26, 33, 38 Meningiomas account for only about 3% of all pediatric intracranial neoplasms, and infantile meningiomas are exceedingly rare. 6, 16, 23, 24, 38, 43 While meningiomas occur more frequently in females in the adult population, they have a slight male predominance in the pediatric population. 16, 17, 24, 25, 38 In children, these tumors have been shown to behave quite differently from their adult counterparts with atypical or malignant (WHO Grade II or III) meningiomas representing around 20%-25% of cases. 25, 43 Pediatric meningiomas have also been reported to recur more frequently than their adult counterparts. 5, 39 However, given the relative infrequency of pediatric meningiomas, less is known about their development, behavior, and optimal treatment.
Pediatric meningiomas have also been reported to recur more frequently than their adult counterparts. 5, 39 However, given the relative infrequency of pediatric meningiomas, less is known about their development, behavior, and optimal treatment.
Several risk factors associated with meningioma have been identified or explored in the general population, including neurofibromatosis Type 1 (NF1) and Type 2 (NF2). 1, 5, 9, 12, 14, 25, 30, 34, 40 Moreover, a history of ionizing radiation has been associated with meningioma formation. 13, 25, 29, 31 Hormonal factors have been hypothesized to be relevant in meningioma formation given the higher incidence of these lesions in adult women. 10, 44 A family history of meningioma may also be a risk factor. 7 The role of smoking is not clear, but cigarette smoking may increase the risk of meningioma. 35 Obesity may also be a risk factor. 32, 42 Every histological subtype of meningioma in adults has been described in the pediatric population. 33 Clear cell (WHO Grade II) and papillary (WHO Grade III) subtypes tend to occur at an earlier age than other subtypes and thus have a higher incidence in the pediatric population. 17, 20, 28, 33, 34, 36, 39 In 1988 chordoid meningiomas were first described in a series of 7 pediatric patients who had symptoms of Castleman disease (fever, anemia, weight loss, and polyclonal hyperglobulinemia). 22, 33 These symptoms resolved with resection of the tumor and returned with lesion recurrence. However, in a year 2000 study of 42 patients with chordoid meningiomas, only 2 patients were in the pediatric age group. 8, 33 In this paper, we report our experience with meningiomas in the pediatric population and review the available literature.
Methods
A retrospective chart review was conducted to identify pediatric patients treated for CNS meningioma at the University of Iowa in the period from 1948 to 2015. The study was approved by the institutional review board at the University of Iowa. Meningioma must have been diagnosed within the first 2 decades of life and the diagnosis confirmed via pathology. The medical records of the identified patients were reviewed. Demographic and clinical data were obtained for all patients: age; sex; body mass index (BMI); pathological diagnosis, grade, and subtype; tumor location; multiplicity; history of other malignancies; NF history; family history of meningioma; smoking history; history of radiation exposure and dose; history of chemotherapy exposure; surgical procedures; radiation treatment for meningioma; recurrence; and latency of recurrence. Associations of baseline patient characteristics with WHO grade and recurrence risk (among the at-risk population) were tested using Fisher's exact test. Results with a p ≤ 0.05 were considered significant. Statistical analysis for this study was performed using SAS software, version 9.4 of the SAS System for Windows (SAS Institute Inc.).
Results
Sixty-seven meningiomas were diagnosed in 39 patients ages 20 years and younger. Table 1 summarizes many key findings in these patients. There were 24 females (62%) and 15 males (38%). Mean age at diagnosis was 14.1 ± 4.57 years (mean ± standard deviation, range 1-20 years). Twenty patients (51%) had tumors involving the skull base. Thirteen patients (33%) had tumors located in the posterior fossa, 8 (20%) had spinal tumors-2 of which also extended intracranially-and 3 (8%) had intraorbital tumors, including 2 optic nerve sheath tumors. Of the patients with spinal involvement, 5 were female (62.5%) and 3 were male (37.5%). Six patients (15%) had multiple lesions at the time of diagnosis. Diagnosis in all but 3 cases was made by pathological examination of a surgical specimen after resection. In 2 cases the diagnosis was made at autopsy. In 1 case, diagnosis of an optic nerve sheath meningioma (fibrous, WHO Grade I) was made via biopsy, but the tumor was not resected. Surgical pathology reports, not the specimens, were reviewed to confirm diagnosis.
Risk Factors

Neurofibromatosis
Eight patients (20%) had meningiomas in the setting of NF. Four patients were identified as having NF2, 2 of whom had multiple intracranial meningiomas. Three of these patients were noted to have concurrent bilateral acoustic neuromas, 1 patient had vagal schwannoma and cervical schwannomas, and 1 patient had multiple intramedullary spinal lesions consistent with ependymomas. Three patients-and an unconfirmed fourth case-had NF1, one of whom also had multiple intracranial meningiomas. In these patients, optic gliomas, cervical neurofibroma, cerebellopontine angle schwannoma, cauda equina schwannoma, schwannoma of appendix and pericardium, and neurofibromas of the oculomotor nerves were also observed. Only 2 patients with NF had a meningioma of a higher grade (both were NF2 patients with atypical meningioma). Two patients with NF2 and 2 patients with NF1 had meningioma recurrence following resection.
Family History of Meningioma
Two patients had a family history of meningioma. In both, the affected family member(s) included the patient's mother. One patient had a mother, a sibling, and several cousins with meningioma, while the other patient only had a mother with a known history of meningioma. Both patients had the clear cell variant of meningioma, whereas only 3 of the 37 patients without a family history of meningioma had clear cell pathology (p = 0.0135 for association between clear cell pathology and family history of meningioma). One of the 2 patients with a family history of meningioma experienced recurrent disease.
Ionizing Radiation History
Prior to the diagnosis of meningioma, 3 patients had a history of radiation exposure for the treatment of acute lymphocytic leukemia earlier in childhood. One of these patients had been treated with 1800 cGy in 10 fractions at the age of 2 years. The patient had then undergone wholebody radiation at a dose of 1200 cGy in 6 fractions prior to bone marrow transplant at the age of 6 years. He died at the age of 14 and the diagnosis of meningioma was made at autopsy. A second patient had been treated with 2400 cGy at the age of 4 years and had received chemotherapy consisting of a combination of agents including vincristine, prednisone, Cytoxan, adriamycin, L-asparaginase, VM-26, Ara-C, 6-mercaptopurine, and triple intrathecal therapy. The patient had had a latency of 11 years before being diagnosed with a left sphenoid wing meningioma, which was resected. The pathology was consistent with an atypical (WHO Grade II) meningioma. A third patient had received craniospinal radiation at 1800 cGy when he was 4 years old. At the age of 16 years, after a 12-year latency period, he was diagnosed with a right sphenoid wing meningioma, which was treated surgically. The surgical pathology revealed microcystic meningioma (WHO Grade I).
Smoking History
Four patients were identified with a history of current (at the time of meningioma diagnosis, 3 patients) or former (1 patient, 12 years old at diagnosis) tobacco use. Three of these 4 patients were female. One patient had pathology consistent with chordoid meningioma; the other 3 patients had WHO Grade I pathology. Two patients with a smoking history experienced tumor recurrence.
Body Mass Index
Limited BMI data were available for the patients in this review; only 12 patients had BMI data readily available from chart review (in some cases, it was calculated from available height and weight data). Of these 12 patients, 2 were slightly underweight, 6 were normal weight, 1 was overweight, and 3 were obese or morbidly obese. The BMIs included in these data ranged from 18 to 47 kg/m 2 . The 3 patients identified as obese or morbidly obese had more aggressive tumor pathology (WHO Grades II and III: chordoid, clear cell, and rhabdoid subtypes). Two of the obese or morbidly obese patients were female; the overweight patient was male. One obese patient experienced meningioma recurrence.
Pathological Subtypes and WHO Grade
Ten patients (26%) had tumors classified as WHO Grade II (22 [33%] of 67 tumors): 5 patients with clear cell meningioma, 1 with chordoid, and 4 with atypical. Of the patients with clear cell histology, 2 had mothers with the same diagnosis. One of these patients also had a sibling and multiple cousins with meningiomas. This patient, notably, had 5 meningiomas; thus, the clear cell subtype made up 13% (9/67) of the meningiomas in our series. One patient with the atypical subtype was found to have 9 meningiomas. Two patients (5%) had WHO Grade III meningiomas (3% of tumors) with one rhabdoid and one papillary subtype. Note that meningioma grading has changed since the earlier patients in our study were diagnosed and that pathology specimens were not available for review for many of these patients. Therefore, it is possible that even more cases of WHO Grade II and III lesions were unaccounted for. Characteristics associated with meningioma WHO grade are demonstrated in Table 2 . Female sex was found to be significantly associated with higher-grade meningioma (Grade II or III vs Grade I, p = 0.0131), as was a younger age (p = 0.0412).
Treatment
Surgery
Of the 39 patients, 36 underwent one or more resection procedures for meningioma. Thirteen patients required multiple surgical procedures (later surgical procedures most often for recurrence). Several patients had 3 or more surgical procedures, and 2 patients each underwent 5 surgical procedures. Details regarding the extent of resection and/or residual tumor versus gross-total resection were not uniformly available. Two patients' meningiomas were identified at autopsy. One of these patients had a history of ionizing radiation for acute lymphoblastic leukemia. The second patient had undergone surgery for vestibular schwannoma and died due to postoperative complications. At autopsy, this patient was found to have 8 intracranial meningiomas. One patient had an optic nerve sheath meningioma, confirmed with biopsy, for which the patient did not receive any further treatment.
Radiation
Thirteen patients were treated with adjuvant radiation therapy (no patient in this series was treated with radiation as a primary therapy without a surgical procedure). The typical cumulative dose ranged from 52.7 to 64.8 Gy for fractionated therapy. One patient was treated with stereotactic radiosurgery in addition to the fractionated therapy for a total of 5 intracranial meningiomas with clear cell pathology. The primary lesion in this patient was treated surgically, whereas the remaining lesions were mainly treated with radiation. Indications for radiation therapy were recurrent disease (8 patients), aggressive pathology (8 patients), multiplicity (2 patients), and subtotal resection and/or surgical inoperability (2 patients). Four patients had aggressive pathology and recurrent disease. The 8 patients with aggressive pathology had chordoid (1), clear cell (3), atypical (2), rhabdoid (1), and anaplastic (1) meningiomas. One patient was treated with fractionated radiotherapy following subtotal resection given the tumor's location at the jugular foramen.
Chemotherapy
One patient was treated with chemotherapy for her meningioma. She underwent subtotal resection of an atypical suprasellar meningioma followed by adjuvant radiation and chemotherapy with bevacizumab and irinotecan. She then received avastin 2 years later for growth of her residual mass. She was 1 year old at the time of the diagnosis of and the first surgery (subtotal resection) for her atypical meningioma. Chemotherapy was used in an attempt to avoid radiation in a very young child. The patient did, at the age of 6 years, ultimately undergo radiation therapy following a second subtotal resection for this very aggressive tumor. As mentioned earlier, 2 patients had a history of chemotherapy treatment for hematological malignancy prior to the diagnosis of meningioma several years later.
Recurrence
In total, 15 patients (38%) had a recurrence of their lesion following resection. The average latency to recurrence was 5.78 ± 5.54 years (range 1-18 years). One patient had a distant metastasis to the lumbosacral region from a posterior fossa clear cell meningioma 6 years after diagnosis. Two years later that same patient had a local recurrence in the posterior fossa. Of the meningiomas that recurred locally, 3 were the clear cell type (WHO Grade II), 1 was anaplastic papillary (WHO Grade III), and 1 was the atypical type, which was treated using subtotal resection with adjuvant radiation and chemotherapy. Ten patients with WHO Grade I pathology experienced a local recurrence. The associations of patient characteristics with meningioma recurrence are shown in Table 3 (included are the 36 patients at risk for recurrence, which excludes 2 patients diagnosed at autopsy and 1 patient who did not undergo resection). Although no risk factors demonstrated a statistically significant association with recurrence, the association of female sex with recurrence trended toward but did not reach statistical significance (52% of females vs 23% of males with recurrent tumors, p = 0.1590; Fig. 1 ).
Discussion
Our findings correspond to much of the previously published data regarding meningiomas in the pediatric population. We found meningiomas to be more common in older children and adolescents, with a mean age of 14 years at diagnosis, and we observed only 1 infant in our series-similar to data in previous studies. 25, 38 Several risk factors predisposing individuals to meningioma at a young age have been identified, for example, ionizing radiation exposure. 13, 25, 29, 31 Ionizing radiation has been shown to cause DNA mutations, either directly or indirectly, via free radicals, which can lead to tumorigenesis. However, the latency to meningioma formation after exposure to cranial radiation is quite long. In 2009, Banerjee et al. looked at acute childhood leukemia patients who had undergone prophylactic cranial radiation. 4 They reported an average latency of 25 years until meningioma formation. Modan et al. retrospectively reviewed nearly 11,000 patients who had undergone radiation for tinea capitis as children. 31 These authors noted a 4-fold increase in the incidence of meningioma. The latency to diagnosis ranged 21 Given this long latency, most meningiomas caused by cranial irradiation in childhood will present in the young adult population rather than the pediatric population. Radiation-induced meningioma tends to have more aggressive behavior, has a higher incidence of recurrence, and is more likely to be multifocal than sporadic meningioma. 5 Nonetheless, 3 patients in our study had a history of ionizing radiation for childhood lymphoproliferative disease. In 2 patients the latency between radiation and meningioma diagnosis was 12 years, and in both of them the pathology was WHO Grade I; latency in the third patient was 11 years and the diagnosis was WHO Grade II atypical meningioma.
In some cases, a family history of meningioma has been identified as a contributing risk factor. 7, 44 However, such a family history has not been reported in prior pediatric meningioma series. In our study, 2 patients had a family history of meningioma, and in both cases the pathology was consistent with clear cell meningioma (p = 0.0891 for association with WHO grade). One patient had 5 meningiomas and required treatment for recurrence. The other patient has not experienced a recurrence to date.
A history of NF may be a risk factor for meningioma in children. 34 Neurofibromatosis Type 2 has been shown to increase the risk of developing intracranial meningioma 1, 5, 12, 14, 25, 30, 34, 40 and has been reported in 6%-39% of pediatric meningioma cases. 33, 37, 38 Neurofibromatosis Type 1 has not shown a similar increased incidence; however, one series of 29 pediatric meningiomas included 7 patients with NF1.
14,25
The NF2-related meningiomas show pathological and genotypic features similar to those in sporadic meningiomas; however, they tend to show multiplicity more frequently than the sporadic meningiomas. 25, 27 Despite a distribution of subtypes similar to that in sporadic meningiomas, NF2-associated meningiomas have been reported to demonstrate increased mitotic activity. 2 Patients with NF2 also have a higher risk of spinal, as well as optic nerve, meningiomas. 25 Meningiomas are seen in up to 53% of NF2 patients and in up to 83% of patients with the more severe phenotype known as the Wishart variant. 15 Nonetheless, it is estimated that only around 1% of all meningioma patients carry a diagnosis of NF2. 34 However, pediatric patients with NF2 are much more likely to present with meningiomas, with a diagnosis in 7%-41% of patients with NF2. 1, 5, 12, 14, 30, 34, 40 We found both patients with a history of NF1 and patients with a history of NF2 in our study of pediatric meningiomas. Eight of the 39 patients had a history of NF: 4 with NF1 and 4 with NF2. This finding is in keeping with those in previous reports. And, in our study, NF was the most commonly observed predisposing factor for meningioma in children. Similar to authors of previous reports, 33 we found that a history of NF did not have a statistically significantly association with WHO grade or recurrence.
Multiplicity has been variably reported in pediatric meningioma. In our series 6 patients had multiple meningiomas. In many cases documented in the literature, multiplicity was wholly accounted for by a concurrent diagnosis of NF2 3, 34, 43 as patients with NF2 are known to be at risk for multiple CNS tumors (not only meningioma). However, multiplicity has been reported in association with radiation-induced meningioma 4, 18 and in sporadic meningioma in children. 11 In our study, 3 of 6 patients with multiple meningiomas had a concurrent diagnosis of NF. In none of the 6 patients were the meningiomas induced by radiation.
Other risk factors, such as the influence of hormones, obesity, and smoking, were somewhat more difficult to assess in our retrospective analysis. We reviewed charts for hormone-related disease or the use of exogenous hormones, but we did not find any evidence to suggest that any of the meningiomas were hormonally influenced. A few patients either had a smoking history or were obese. While the presence of these factors may have contributed to the risk of developing meningioma in these patients, it would be difficult to make such a conclusion, and no significant associations with WHO grade or recurrence were identified.
While prior studies have indicated a male predominance for meningioma in the pediatric population-the converse of the female predominance in adults-we did not find a male predominance in our study. 16, 17, 24, 25, 38 In fact, female patients outnumbered the male patients (24:15). Moreover, we found a significant association between female sex and WHO grade, with higher-grade meningiomas observed more frequently in females (46% Grades II and III in females vs 7% Grades II and III in males, p = 0.0131). To our knowledge, this finding has not been reported. Female sex was the only significant risk factor we identified for a higher WHO grade. We also found a nonsignificant trend toward higher recurrence rates in females (52% vs 23%, p = 0.1590; Fig. 1 ), which did not seem to be wholly accounted for by a higher WHO grade (recurrence rate of 54% in females with Grade I meningioma vs 45% in females with Grade II or III meningioma, not significant). This challenges the notion that meningioma is a disease process affecting predominantly males in the pediatric population. It also draws attention to the fact that among children and adolescents with meningioma, girls may be at higher risk than boys for aggressive tumors.
Although pediatric meningiomas are quite rare, they are a recognized disease entity in the pediatric population and should be considered in the differential diagnosis of a newly diagnosed extraaxial cranial or spinal mass lesion, particularly when it demonstrates characteristic imaging features such as a dural tail, convexity, or skull base location and a homogeneous enhancement pattern. While certain risk factors, such as a history of NF, prior ionizing radiation, or a family history of meningioma, should raise suspicion for a diagnosis of meningioma, the absence of these predisposing factors does not effectively eliminate the risk of meningioma in the pediatric population. The majority of patients in our series (26 [67%] of 39) had none of the above risk factors.
Pediatric meningiomas tend to be more aggressive than their adult counterparts. This is reflected in the literature as well as in our findings. 24, 43 Approximately onethird of the patients in our study had more aggressive pathology: 31% (12 of 39) of patients had WHO Grade II or Grade III pathology. We also found that a female sex and younger age were significantly associated with a higher WHO grade pathology-which to our knowledge has not been previously reported. Five of those cases (42%) were the clear cell subtype. Given pediatric meningiomas' propensity for aggressive behavior, early intervention in newly diagnosed cases should be considered, or at least frequent follow-up imaging in the case of a small lesion. Pediatric meningiomas also tend to recur more frequently than their adult counterparts. 5, 39 In our study, 15 (42%) of the 36 patients who had undergone resection had lesion recurrence, with a mean latency to recurrence of 5.78 years. Among the 15 patients with recurrence, 5 (33%) had WHO Grade II or III pathology (Figs. 2 and 3) , and the lesions in 3 of them were the clear cell subtype. It is well established that WHO Grade II and III lesions have a higher likelihood of recurrence; however, our findings highlight the fact that even low-grade lesions in children can behave more aggressively and thus require more diligent surveillance for recurrence. Among our patients with WHO Grade I pathology, the recurrence rate was 42% (10 of 24), which was not significantly different from the recurrence rate among patients with WHO Grade II or III pathology. This finding suggests that even WHO Grade I meningiomas in children may behave more like adult atypical meningiomas than classic adult meningothelial meningiomas. 19 Given this finding, it is possible that the WHO grading system may not adequately reflect how ag- gressive a meningioma will be in this age group and that further classification is necessary.
Study Limitations
Our study has several limitations. As a retrospective review, certain clinically relevant data, such as extent of resection, were not uniformly available, and we were without the means to objectively define such criteria through chart review. Furthermore, resection is undoubtedly relevant with regard to recurrence rates. It is possible that the higher recurrence rates we observed are in fact related to the extent of initial resection and actually represent tumor progression. This is especially relevant with regard to the earlier cases from the pre-MRI era in which verification of the extent of resection was extremely limited. Thus, it is difficult to distinguish true recurrence from progression in this series. However, by the same token, many valuable historical series would have to be disregarded on these premises. Furthermore, advances in adjuvant therapy such as stereotactic radiosurgery were unavailable in the earlier patients in the study, thus potentially influencing recurrence rates for subtotally resected tumors.
Another limitation is the inconsistency of pathology reporting in the earlier cases. It is notable that for a number of patients, the pathology reports actually predate the first publication of the WHO classification of tumors of the CNS in 1979. 41 Many of these cases provided descriptive pathology reports from which the current WHO grade could be inferred (for example, description of meningothelial, fibrous/fibroblastic, or psammomatous meningioma can safely be categorized as WHO Grade I, while the description of atypical meningioma can be safely determined to be WHO Grade II). However, 15 patients in our series (42%) had pathology predating the first WHO classification publication, and any inferences about pathology grade as it relates to recurrence rate or treatment in this series must take this into consideration.
Conclusions
Meningiomas are relatively rare lesions in the pediatric population. Although there are several known risk factors, many of which were observed in the patients in our study, the absence of these risk factors does not eliminate the meningioma risk; sporadic meningiomas can be observed in children. In our series, meningiomas were observed more frequently in girls than in boys and exhibited more aggressive pathological histology and WHO grade in girls than in boys. Pediatric meningioma should be thought of as an entity separate from its adult counterpart as it behaves more aggressively on the whole. Early treatment should be considered, and close follow-up is mandatory.
